TrialSignal transduction and targeted therapy2025

Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study.

Mengqing Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.